Trial Profile

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 27 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Berzosertib (Primary) ; Sacituzumab govitecan (Primary)
Indications Neuroendocrine tumours; Prostate cancer; Small cell lung cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use

22 Apr 2026 Status changed from recruiting to active, no longer recruiting.
24 Mar 2026 Planned End Date changed from 1 Mar 2027 to 1 Mar 2029.
24 Mar 2026 Planned primary completion date changed from 1 Mar 2026 to 1 Mar 2028.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com